FDA — authorised 4 April 1997
- Application: NDA020705
- Marketing authorisation holder: VIIV HLTHCARE
- Local brand name: RESCRIPTOR
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Rescriptor in United States
FDA authorised Rescriptor on 4 April 1997
Marketing authorisation
Other Immunology approved in United States
Frequently asked questions
Is Rescriptor approved in United States?
Yes. FDA authorised it on 4 April 1997.
Who is the marketing authorisation holder for Rescriptor in United States?
VIIV HLTHCARE holds the US marketing authorisation.